Dr. Brown on Idelalisib Plus Rituximab in CLL

Video

Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, discusses the development of the novel PI3K-delta inhibitor idelalisib as a treatment for patients with chronic lymphocytic leukemia.

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the development of the novel PI3K-delta inhibitor idelalisib as a treatment for patients with chronic lymphocytic leukemia (CLL).

There are currently 3 large registration trials exploring idelalisib, Brown states. One of these trials, a phase III study combining idelalisib with rituximab for patients with previously treated CLL, was halted early due to a high-level of efficacy in an interim analysis conducted by an external Data Monitoring Committee.

The median progression-free survival (PFS) for patients treated with idelalisib plus rituximab has not yet been reached. For rituximab plus placebo, the median PFS was 5.5 months. At the 24-week analysis of the trial, the PFS rate was 93% compared to 46%, for idelalisib and placebo, respectively.

<<<

View more from the 2013 ASH Annual Meeting

Related Videos
Saad J. Kenderian, MB, CHB
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Guenther Koehne, MD, PhD
Lori A. Leslie, MD, an expert on lymphoma
Lori A. Leslie, MD, an expert on lymphoma
A panel of 4 experts on MDS
Jennifer Brown, MD, PhD
Patrick I. Borgen, MD